Top

Journal of Gastrointestinal Surgery

Published in:

01-11-2010 | 2010 SSAT Poster Presentation

Surgical Resection and Multidisciplinary Care for Primary and Metastatic Pancreatic Islet Cell Carcinomas

Authors: Shaun McKenzie, Wendy Lee, Avo Artinyan, Brian Mailey, Alessio Pigazzi, Joshua Ellenhorn, Joseph Kim

Published in: Journal of Gastrointestinal Surgery | Issue 11/2010

Abstract

Introduction

The role of multidisciplinary management of islet cell cancers (ICC) has not been fully investigated in a population-based setting.

Methods

The Los Angeles County Cancer Surveillance Program was assessed for patients with ICC between the years 1982 to 2006. Patients were stratified by treatment received and clinicopathologic characteristics and survival were compared.

Results

We identified 236 patients with ICC; 86 patients underwent curative-intent surgery with median survival for local, regional, and distant disease of 17.3, 12.2, and 4.0 years, respectively. In comparison, 102 patients underwent medical management alone; survival was significantly shorter when compared to the surgical cohort for local, regional, and distant disease (p < 0.05). To determine whether adjuvant chemotherapy was associated with improved survival, we compared patients who underwent surgery alone compared to patients who underwent surgery followed by adjuvant chemotherapy. Although patients with metastatic disease had 3-year longer survival with adjuvant chemotherapy, these improvements in survival were not statistically significant.

Conclusion

Surgical resection was associated with improved survival compared to medical management for any extent of disease in patients with ICC. Furthermore, adjuvant chemotherapy was not associated with survival but does warrant further examination in patients with metastatic disease.

Capelli P, Martigoni G, Pedica F, Falconi M, Antonello D, Malpeli G, Scarpa A. Endocrine neoplasms of the pancreas: pathologic and genetic factors. Arch Pathol Lab Med 2009;133(3):350–364.PubMed

O’Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. EJSO 2008;34(3):324–332.PubMed

Ehehalt F, Saeger H, Schmidt M, Grutzmann R. Neuroendocrine tumors of the Pancreas. Oncologist 2009;14(5):456–467.CrossRefPubMed

Hochwald S, Zee S, Conlon K, Colleoni R, Louie O, Brennan M, Klimstra D. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20(11):2633–2642.CrossRefPubMed

Abood G, Go A, Malhotra D, Shoup M. The surgical and systematic management of neuroendocrine tumors of the pancreas. Surg Clin North Am 2009;89(1):249–266.CrossRefPubMed

Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, Bulcher M. Clinical outcome and long term survival in 118 consecutive patients with neuroendocrine tumors of the pancreas. Br J Surg 2008;95(5):627–635.CrossRefPubMed

Schurr P, Strate T, Rese K, Kaifi J, Reichelt U, Petri S, Kleinhans H, Yekebas E, Izbicki J. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumours: an institutional experience. Ann Surg 2007;245(2):273–281.CrossRefPubMed

Teh S, Deveney C, Sheppard B. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg 2007;193(5):610–613.CrossRefPubMed

You DD, Lee HG, Pail HG, Heo JS, Choi SH, Choi DW. The outcomes after surgical resection in pancreatic endocrine tumors: an institutional experience. EJSO 2009;35(7):728–733.PubMed

10.

Nguyen S, Angel L, Divino C, Schluender S, Warner R. Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol 2007;96(5):397–403.CrossRefPubMed

11.

Hodul P, Strosberg J, Kvols L. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control 2008;15(4):314–321.PubMed

12.

Yao J, Eisner M, Leary C, Dagohoy C, Phan A, Rashid A, Hassan M, Evans D. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14(12):3492–3500.CrossRefPubMed

13.

Chamberlain R, Canes D, Brown K, Saltz L, Jarnagin W, Fong Y, Blumgart L. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190(4):432–445.CrossRefPubMed

14.

Kim J, Sun C, Mailey B, Prendergast C, Artinyan A, Bhatia S, Pigazzi A, Ellenhorn J. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol 2010;21:152–160.CrossRefPubMed

15.

Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave G, Panzuto F, Scarpa A, Falconi M. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumors. Ann Oncol 2008;13(5):903–908.CrossRef

16.

Liang H, Wang P, Wang X, Wang J, Hao X. Management of nonfunctioning islet cell tumors. World J Gastroenterol 2004;10(12):1806–1809.PubMed

17.

Hill J, McPhee J, McDade T, Zhou Z, Sullivan M, Whalen G, Tseng J. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009;115(4):741–751.CrossRefPubMed

18.

Bilimoria K, Talamonti M, Tomlinson J, Stewart A, Winchester D, Ko C, Bentrem D. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 2008;247(3):490–500.CrossRefPubMed

19.

Chung J, Choi D, Jo S, Heo J, Choi S, Kim Y. Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment. World J Surg 2007;31(3):579–585.CrossRefPubMed

20.

Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, Scarpa A, Pederzoli P, Falconi M. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 2009;41(1):49–55.CrossRefPubMed

21.

Bloomston M, Muscarella P, Shah M, Frankel W, Al-Saif O, Martin E, Ellison E. Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg 2006;10(10):1361–1370.CrossRefPubMed

22.

House M, Cameron J, Lillemoe K, Schulick R, Choti M, Hansel D, Hruban R, Maitra A, Yeo C. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 2006;10(1):138–145.CrossRefPubMed

23.

Norton J, Warren R, Kelly M, Zuraek M, Jensen R. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134(6):1057–1063.CrossRefPubMed

24.

Kaltsas G, Besser M, Grossman A. The diagnosis and management of advanced neuroendocrine tumors. Endocrine Rev 2004;25(3):458–511.CrossRefPubMed

25.

Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumors. Ann Oncol 2001;12(S2):S111–S114.CrossRefPubMed

26.

Strosberg J, Kvols L. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007;16(2):219–214.CrossRefPubMed

27.

Maire F, Hammel P, Kianmanesh R, Hentic O, Couvelard A, Rebours V, Zappa M, Raymond E, Sauvanet A, Louvet C, Levy P, Belghiti J, Ruszniewski P. Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 2009;145(1):69–75.CrossRefPubMed

28.

Frank M, Klose K, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and α-interferon: effect of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94(5):1381–1387.PubMed

29.

Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday T. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 2005;80(4):502–506.CrossRefPubMed

30.

Faiss S, Pape U, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken E, Wiedenmann B, International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21(14):2689–2696.CrossRefPubMed

Title: Surgical Resection and Multidisciplinary Care for Primary and Metastatic Pancreatic Islet Cell Carcinomas
Authors: Shaun McKenzie
Wendy Lee
Avo Artinyan
Brian Mailey
Alessio Pigazzi
Joshua Ellenhorn
Joseph Kim
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 11/2010
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-010-1225-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Surgical Resection and Multidisciplinary Care for Primary and Metastatic Pancreatic Islet Cell Carcinomas

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2010

Pancreaticoduodenectomy can be Performed Safely in Patients Aged 80 years and Older

Pre-operative Nomogram to Predict Risk of Peri-operative Mortality following Liver Resections for Malignancy

Disappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned?

Preservation of Replaced or Accessory Right Hepatic Artery During Pancreaticoduodenectomy for Adenocarcinoma: Impact on Margin Status and Survival

Comparing Complications of Esophagectomy and Pancreaticoduodenectomy and Potential Impact on Hospital Systems Utilizing the Accordion Severity Grading System

Prophylactic Pancreatectomy for Intraductal Papillary Mucinous Neoplasm Does Not Negatively Impact Quality of Life: A Preliminary Study